Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani: We Developed a Comprehensive Health System so as not to Exclude any Citizen from the Universal Coverage

 
NNA- The administration and justice committee held a meeting presided by Deputy Robert Ghanem in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani and deputies: Hani Kobaisy, Elie Aoun, Serge Torsarkisian, Atef Majdalani, Ghassan Moukhayber, Nawaf Mousawi, the representatives of Health Ministry Fadi Mosallem and the Ministry of Social Affairs Adnan Naser Eddine, Director General of the National Social Security Fund Dr. Muhammad Karaki, Head of NSSF Diwan Chawki Abou Nassif, the representative of the Ministry of Finance Nahla Boustani, the President of the General Confederation of Lebanese Workers Bechara Asmar.

Ghanem

“This is the eighth meeting of the administration and justice committee to study the so-called visa coverage card; the mandatory universal healthcare coverage suggested by Dr Atef Majdalani and studied by the Health committee. When H.E. Hasbani became Health Minister, he asked that this subject be more comprehensive. A study was conducted to include the majority of the Lebanese citizens,” stated the committee’s president.

Hasbani

“I would like to thank and congratulate the administration and justice committee for discussing the proposal of the law submitted by Deputy Atef Majdalani. The Ministry of Public Health made observations based on a recent study this year on the health coverage or the mandatory universal health care. The detailed study with experts includes many observations made on this subject to develop the system so as not to exclude any citizen from the universal coverage; primary health care, inpatient and outpatient services,” outlined Hasbani.

Majdalani

“I would like to thank my colleague Mr. Robert Ghanem, the president of the administration and justice committee for his help and seriousness in scheduling the meetings of the committee and contribution in the discussions. I thank as well Health Minister Ghassan Hasbani for the amendments of Health Ministry to expand the network of social and health solidarity in the proposal of the law we suggested in 2013,” said Majdalani.
    ...
    131
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD02 ESPEROCT BioTech Turoctocog Alfa pegol (recombinant coagulation factor VIII) - 1000IU/Vial 1000IU/Vial Injectable powder for solution+diluent 72,849,268 L.L
B02BD04 BENEFIX BioTech Nonacog alfa (recombinant coagulation factor IX) - 500IU 500IU Injectable powder for solution+diluent 27,390,281 L.L
B02BD06 WILATE 500 BioHuman Von Willebrand Factor - 500IU, Blood Coagulation Factor VIII - 500IU Injectable powder for solution+diluent 32,399,164 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 2mg 2mg (100KIU) Injectable powder for solution+diluent 105,957,406 L.L
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent 16,902,713 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent 57,890,287 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 5mg 5mg (250KIU) Injectable powder for solution+diluent 264,894,762 L.L
B02BD08 RECOFACT VII BioTech Eptacog alfa (activated) recombinant - 1.2mg 1.2mg Injectable powder for solution+diluent 47,533,131 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 433,869 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 MEDAXONUM G Ceftriaxone (disodium) (Vial) - 500mg, Lidocaine (ampoule) - 500mg Injectable powder for solution+diluent 307,740 L.L
J01DD04 TRIAXONE G Ceftriaxone (sodium) - 500mg 500mg Injectable powder for solution+diluent 356,118 L.L
J01DD04 AXONE 1G IM G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 438,093 L.L
H01AC01 GENOTROPIN BioTech Somatropin recombinant - 5.3mg/1.15ml 5.3mg/1.15ml Injectable powder for solution+diluent 4,724,854 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 643,765 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) - 1g Injectable powder for solution+diluent 568,253 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 508,100 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 508,100 L.L
H01AC01 GENOTROPIN GOQUICK BioTech Somatropin recombinant - 12mg/ml 12mg/ml Injectable powder for solution+diluent 25,170,264 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 643,765 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) - 1g Injectable powder for solution+diluent 568,253 L.L
J01DD04 MEDAXONUM G Ceftriaxone (disodium) - 1g 1g Injectable powder for solution+diluent 438,093 L.L
J01DD04 MEGION G Ceftriaxone (disodium 3.5 hydrate) - 1g 1g Injectable powder for solution+diluent 552,259 L.L
J01DD04 MESPORIN-1000 IM G Ceftriaxone (sodium) - 1g 1,000mg Injectable powder for solution+diluent 417,935 L.L
    ...
    131
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025